Implementation of polygenic risk score guided breast cancer precision prevention
The project has been supported by the Norway Grants Green ICT programme.
Project AnteNOR
Project implementation period: 01.07.2021-30.04.2024
Grant amount: 761 360,20 €
Total budget: 1 523 025 €
Antegenes has registered and CE-certified a breast cancer genetic risk test AnteBC that is based on polygenic risk scores technology. AnteBC allows to differentiate women’s genetic predisposition to breast cancer and to make more specific recommendations for the prevention and early detection of breast cancer.
Project’s goal
The general objective of the project is to implement AnteBC test as part of a breast cancer screening routine in Norway. Current breast cancer screening is only age based but can decrease mortality by around 20% if invitations account for AnteBC results. The project activities deploy AnteBC to Norwegian healthcare: a consortium of partners assesses the test performance in the Norwegian population, conducts a clinical pilot study and assembles technical documentation to prepare for public reimbursement.
Project result
By the end of the project, the performance of the AnteBC test based on the genetic data of the Norwegian population has been analyzed, a successful clinical trial has been conducted in Norwegian clinical settings and the necessary scientific and regulatory documentation has been developed for the implementation of breast cancer precision prevention. Also, necessary trainings for healthcare professionals have been conducted.
Partners
Oslo Cancer Cluster
Osly Universitetsykehus
Vestre Viken Hospital Trust
Oslo University
Osly Universitetsykehus
Vestre Viken Hospital Trust
Oslo University
About Us
Antegenes is an Estonian health technology company and medical laboratory with a goal to develop and implement advanced genetic tests based on polygenic risk scores technology for the prevention of major complex diseases.
